Time and Date: Monday, March 13, 2023 at 5:30 PM - 7:00 PM CDT
Faculty: Savitri Krishnamurthy, MD and Jorge Reis Filho, MD, PhD
Breast cancer treatment decisions are increasingly being influenced by molecular biomarker findings, and testing expectations and standards are anticipated to change as more targeted agents make their way into clinical practice. This program provides an overview of the benefits and challenges of testing for various molecular biomarkers in breast cancer from the perspective of the pathologist. More specifically:
New and Emerging Molecular Biomarkers in Breast Cancer
Savitri Krishnamurthy, MD, of the MD Anderson Cancer Center, will discuss new and emerging molecular biomarkers in breast cancer, including PIK3CA, BRCA1/2, ESR1, AKT, PD L1, MSI, MMR, and tumor-infiltrating lymphocytes.
New and Emerging Molecular Biomarker Testing Technologies in Breast Cancer
Jorge Reis Filho, MD, PhD, from the Memorial Sloan Kettering Cancer Center, will address new and emerging molecular biomarker testing technologies in breast cancer, including a comparison of NGS testing of tissue versus ctDNA, along with the utility of ddPCR and other technologies.
The webinar is possible through MphaR. This content is not available for continuing medical education. If you continue to register, you are acknowledging that your information will be shared with the company, including your name, degrees, institution, NPI number, mailing address, email address, and phone number. USCAP has no control over the use of this information.
The information presented represents the opinion of the presenters and is not necessarily the view of USCAP. USCAP does not endorse the products or services. The webinar is possible through MphaR. This activity is not available for CME.